| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H15Cl2N5 |
| Molecular Weight | 288.176 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NC(=N)NC(=N)NC1=CC=C(Cl)C(Cl)=C1
InChI
InChIKey=ISZNZKHCRKXXAU-UHFFFAOYSA-N
InChI=1S/C11H15Cl2N5/c1-6(2)16-10(14)18-11(15)17-7-3-4-8(12)9(13)5-7/h3-6H,1-2H3,(H5,14,15,16,17,18)
| Molecular Formula | C11H15Cl2N5 |
| Molecular Weight | 288.176 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Chlorproguanil is a biguanide. Chlorproguanil is active against P. falciparum and P. malariae. Chlorproguanil acts by inhibition of dihydrofolate reductase after cytochrome P450-catalysed cyclization. Chlorproguanil combined with dapsone was developing for the treatment of falciparum malaria. The anti-malarial combination chloroproguanil and dapsone has been withdrawn following demonstration of post-treatment haemolytic anaemia in glucose-6-phosphate dehydrogenase (G6PD) deficient patients in a phase III
clinical trial.
Originator
Approval Year
PubMed
|
|
SALT/SOLVATE -> PARENT |
|
Showing 1 to 1 of 1 entries
